Global Cardiovascular Risk Profile and Cerebrovascular Abnormalities in Presymptomatic Individuals with CADASIL or

Dorothee Schoemaker1,2, Lina Velilla-Jimenez3, Yesica Zuluaga3

  • 1Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Insights

Cardiovascular risk factors impact brain health. In cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), higher cardiovascular risk correlated with brain changes, suggesting benefits from risk factor management.

Area of Science:

  • Neurology
  • Cardiology
  • Neuroimaging
  • Genetics

Background:

  • Cardiovascular risk factors are known to increase the likelihood of developing dementia, including Alzheimer's disease and vascular dementia.
  • Autosomal dominant mutations can lead to the early onset of dementia, providing a model to study disease mechanisms.

Purpose of the Study:

  • To investigate the influence of the global cardiovascular risk profile on early cognitive and neuroimaging features in individuals with autosomal dominant mutations causing early-onset dementia.
  • To compare these effects in autosomal dominant Alzheimer's disease (ADAD) and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).

Main Methods:

  • Study included 85 participants: 20 with PSEN1 E280A mutation (ADAD), 20 with NOTCH3 mutations (CADASIL), and 45 non-carriers.
  • All subjects underwent clinical, neuropsychological, and MRI evaluations.
  • Global cardiovascular risk was assessed using the Framingham Cardiovascular Risk Profile (FCRP) score.

Main Results:

  • In CADASIL patients, a higher FCRP score was linked to reduced hippocampal volume and increased severity of cerebral microbleeds, lacunes, and basal ganglia perivascular space enlargement.
  • No significant association between FCRP score and neuroimaging measures was found in ADAD or non-carrier subjects.
  • FCRP score correlated with executive function in non-carriers but not in CADASIL or ADAD patients.

Conclusions:

  • Individuals with CADASIL and other forms of vascular cognitive impairment may particularly benefit from interventions targeting cardiovascular risk factors.
  • Early management of cardiovascular health is crucial for mitigating neuroimaging changes associated with vascular dementia subtypes.
Abstract

Related Concept Videos

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
183
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
565
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
941
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
432
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
124
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
454